hexenoyl group is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-07-09. Where a claim depends on a specific study, the study is described rather than over-claimed.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
监管记录显示，特沙莫瑞林于 2010 年在美国首次获得批准，用于人类免疫缺陷病毒感染相关的脂肪营养不良患者。批准依据来自降低内脏脂肪的临床试验，而非体重或瘦体重的普遍改善。后续出现了不同制剂版本，但其核心适应症保持一致。关于长期心血管结局和死亡率影响，现有证据仍不充分。
在临床研究之外，特沙莫瑞林常被讨论为生长激素分泌促进剂，但这一说法需要限定。它并不等同于生长激素本身，也不属于普通减重药物。部分研究关注其减少腹部脂肪和改善脂质谱的潜力，另一些研究则关注胰岛素抵抗和 IGF-1 升高等信号。这些效应的临床意义仍在评估中，尚未形成统一结论。
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | GHRH receptor agonist |
| Residue count | 44 amino acids | N-terminal trans-3-hexenoyl group |
| Approximate mass | About 5.1 kDa | Derived from the peptide sequence |
| Primary target | Pituitary GHRH receptor | Somatotroph cells of the anterior pituitary |
| Downstream marker | IGF-1 | Measured indirectly in circulation |
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
=== Aging === Studies in female mice have shown that both supraoptic nucleus (SON) and paraventricular nucleus (PVN) lose approximately one-third of IGF-1R immunoreactive cells with normal aging. Also, old calorically restricted (CR) mice lost higher numbers of IGF-1R non-immunoreactive cells while maintaining similar counts of IGF-1R immunoreactive cells in comparison to old-Al mice. Consequently, old-CR mice show a higher percentage of IGF-1R immunoreactive cells, reflecting increased hypothalamic sensitivity to IGF-1 in comparison to normally aging mice.
== Early life == In his senior year at high school, Hille and seven other schoolmates from Peninsula Grammar lodged themselves into a station wagon and crashed it 500m up the road from where they took off in South Frankston. Three of the boys in the car were killed, and the other three seriously injured, but Hille was not injured. The accident report claims that Hille was wearing his seatbelt, which is why he has appeared on commercials about buckling up when driving.
One possible advantage of the therapeutic approach of blocking viral entry (as opposed to the currently dominant approach of viral enzyme inhibition) is that it may prove more difficult for the virus to develop resistance to this therapy than for the virus to mutate or evolve its enzymatic protocols.
As tribal healers developed into doctors, it spurred on a primitive pharmaceutical industry that included traders who would travel overseas bringing herbs that would be used for specific wounds. Soon, like most industries, patients began to skip the doctors altogether and purchased the herbs directly from the traders who were also aware of the effects and quantities that should be taken while also informing their "patients" of them. These merchants that supplied people with herbs were known as rhizotomiki, or gatherers of roots, in Ancient Greece. The earliest known list of herbs and remedies was probably written for these herbal merchants. The earliest known to men is the Rhizotomika of Diocles of Carustius, a student of Greek philosopher Aristotle. This book includes the author's observation of the effects of the herbal medicine on specific parts of the human body. This then became the beginning of scientific research on herbal remedies on humans, which has been modified and significantly changed from modern wound remedies. The Greeks also acknowledged the importance of wound closure, and were the first to differentiate between acute and chronic wounds, calling them "fresh" and "non-healing", respectively. Galen of Pergamum, a Greek surgeon who served Roman gladiators circa 120–201 A.D., made many contributions to the field of wound care. The most important was the acknowledgment of the importance of maintaining wound-site moisture to ensure successful closure of the wound.
Sources: en.wikipedia.org
== Causes == The development of vitiligo is linked to aberrant attachments between melanocytes (which produce melanin) and laminins, a kind of glycoprotein. When the basement membrane (the fibrous layer between cells and adjacent connective tissue) becomes enriched in laminin-332, melanocytes attach to that protein instead of the normal laminin-211 (via an integrin receptor instead of dystroglycan). Rather than disappearing, melanocytes appear to dedifferentiate and thus lose the ability to produce pigment, altering the actin cytoskeleton of affected cells. Melanocyte loss may also be caused by the activation of the signaling pathway formed by Janus kinases (JAKs) and signal transducer and activator of transcription proteins (STATs), being triggered by T cells and creating a positive feedback loop with interferon-gamma (IFN-γ) chemokines (a form of cytokine signaling protein) secreted by keratinocytes, the primary cell type of the epidermis. According to one study, segmental vitiligo (SV) is linked to the dysfunction of sympathetic nerves and demonstrates increased adrenoceptor responses in the affected areas as well as three times higher local blood flow. Meanwhile, a blood flow increase of about 1.5 times occurs in the more common nonsegmental vitiligo (NSV). The disorder has occurred in recipients of bone marrow and lymphocytes from donors with vitiligo.
Complete: Data should not be missing Consistent: Data should not deviate from a set style, for example, the abbreviation N/A should only be used for one phrase Enduring: Documents should be designed to last a reasonable length of time Available: Documents should be retrievable. GxPs require that a quality system be established, implemented, documented, and maintained. As explained above, documentation is a critical tool for ensuring GxP adherence. For more information, see good manufacturing practice.
== F == Favorskii reaction Favorskii rearrangement Favorskii–Babayan synthesis Fehling test Feist–Benary synthesis Fenton reaction Ferrario–Ackermann reaction Ferrier carbocyclization Ferrier rearrangement Fétizon oxidation Fiesselmann thiophene synthesis Finkelstein reaction Fischer indole synthesis Fischer oxazole synthesis Fischer peptide synthesis Fischer phenylhydrazine and oxazone reaction Fischer glycosidation Fischer–Hepp rearrangement Fischer–Speier esterification Fischer Tropsch synthesis Fleming–Tamao oxidation Flood reaction Folin–Ciocalteu reagent Formox process Forster reaction Forster–Decker method Fowler process Franchimont reaction Frankland synthesis Frankland–Duppa reaction Fráter–Seebach alkylation Free radical halogenation Freund reaction Friedel–Crafts acylation Friedel–Crafts alkylation Friedländer synthesis Fries rearrangement Fritsch–Buttenberg–Wiechell rearrangement Fujimoto–Belleau reaction Fujiwara–Moritani reaction Fukuyama coupling Fukuyama indole synthesis Fukuyama reduction
== Using data obtained to find concentration of unknown == In summary, in order to find a standard curve, one must use varying concentrations of BSA (Bovine Serum Albumin) in order to create a standard curve with concentration plotted on the x-axis and absorbance plotted on the y-axis. Only a narrow concentration of BSA is used (2-10 ug/mL) in order to create an accurate standard curve. Using a broad range of protein concentration will make it harder to determine the concentration of the unknown protein. This standard curve is then used to determine the concentration of the unknown protein. The following elaborates on how one goes from the standard curve to the concentration of the unknown. First, add a line of best fit, or Linear regression and display the equation on the chart. Ideally, the R2 value will be as close to 1 as possible. R represents the sum of the square values of the fit subtracted from each data point. Therefore, if R2 is much less than one, consider redoing the experiment to get one with more reliable data.
== Veterinary use == Methadone is a common perioperative analgesic in cats and dogs with a variety of routes of administration. Methadone in combination with acepromazine provides greater sedation than the equivalent combination involving morphine or butorphanol. Methadone's depressive effect on the cardiovascular system is approximately twice as strong as morphine. Methadone is contradicated for gastroduodenoscopy. Methadone provides greater analgesia than buprenorphine for orthopaedic and ovariohysterectomy procedures in dogs. Fluconazole and methadone given concurrently as a subcutaneous administration twice over a 6 hour period can provide analgesia for 12–24 hours. Methadone can be used for sedation in horses but is less effective than butorphanol, it can be combined with detomidine, which improves efficacy but can cause ataxia although the combination with detomidine has significantly less cardiovascular depressive effects than a combination with acepromazine. Methadone may be more effective as an analgesic in horses when adiminstered parenterally or epidurally as opposed to intravenously. Opioids are uncommon for livestock due to legislation surrounding usage but intravenous methadone is an effective analgesic in sheep and epidural methadone is an effective analgesic in cattle and sheep. Methadone comes as levomethadone and dextromethadone with the former sometimes combined with the anti-cholinergic fenpipramide. Oral methadone is poorly absorbed in most species.
Sources: en.wikipedia.org
It mirrors the 44-residue form of human growth hormone-releasing hormone. A hexenoyl group on the N-terminal tyrosine distinguishes it from the unmodified hormone. The change is intended to improve resistance to enzymatic breakdown.
The N-terminal modification reduces cleavage by circulating peptidases, so the peptide persists longer than native GHRH. That persistence is the main rationale for the synthetic design. Comparative half-life values in humans are reported in regulatory review documents rather than in general reference literature.
Reductions in visceral adipose tissue have been measured in controlled studies of defined populations. Whether the effect generalizes to other groups and persists after treatment stops is less clear. Longer-term outcome data remain limited.
特沙莫瑞林是国际非专利名称，指一种经过 N 端修饰的生长激素释放激素类似物。它被归类为合成肽，序列与 GHRH(1-44) 密切相关。该名称不指代任何特定品牌或剂型。